Effects of L-Citrulline or Citrulline-malate on Neuromuscular Performance in Resistance-trained Adults

November 3, 2022 updated by: Lucas Jurado-Fasoli, Universidad de Granada

Malate or Not?: Effects of L-Citrulline or Citrulline-malate on Neuromuscular Performance in Resistance-trained Adults

The main aim of this study is to compare the effects of L-Citrulline vs. Citrulline-malate on neuromuscular performance (maximal dynamic strength and maximal endurance strength) in resistance-trained adults.

Study Overview

Detailed Description

Nitric oxide (NO) is a ubiquitous gaseous molecule that plays a critical role in the regulation of cardiovascular function and in the signaling of multiple cellular processes. Specifically, NO could reduce the oxygen cost of exercise and adenosine triphosphate (ATP) in the production of muscle contractile force, improving calcium handling, glucose uptake and mitochondrial efficiency in muscle fibers. Therefore, it has been suggested that increasing the availability of NO through the oral intake of food and nutritional supplements may be useful to delay the onset of fatigue and improve performance in high-intensity efforts.

L-citrulline is a nonessential amino acid involved in the urea cycle that acts as an endogenous precursor of L-arginine, being a more efficient alternative to L-arginine to increase the plasma concentration of L-arginine through the nitric oxide synthase (NOS) pathway.

On the other hand, citrulline malate is an organic salt of L-citrulline and malate which has been shown to exert a small but significant ergogenic effect in different high-intensity efforts compared to a placebo. However, no study to date has compared L-citrulline VS. citrulline malate to assess whether there is an additive effect from malate to exercise performance.

50 resistance-trained adults (50% women) will be randomized into three conditions (L-citrulline, citrulline-malate and placebo conditions) with 48 hours of separation between conditions. 48h previous to the randomization the participants will perform a familiarization to avoid the learning effects.

Each evaluation day will conform to the following tests:

  • Maximal dynamic strength of lower- and upper-body
  • Maximal endurance strength of lower- and upper-body

Study Type

Interventional

Enrollment (Actual)

50

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Granada, Spain, 18011
        • Jonatan Ruiz Ruiz

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 35 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Healthy male or female
  • Ages 18-30years
  • BMI: 18-30.0 kg/m2
  • Stable weight over the last 3 months (body weight changes<3kg)
  • Previous experience in resistance training (i.e., at least 1 year with a frequency of two or more training sessions per week),
  • Participant must be capable and willing to provide consent, understand exclusion criteria, instructions and protocols.

Exclusion Criteria:

  • History of chronic diseases (renal disease, diabetes, cardiovascular disease, cancer, VIH, hepatic disease, food disorders)
  • Pregnant, planning to become pregnant, or breastfeeding
  • Have been treated previously or during the study period with prescription drugs:

antihypertensive, lipid lowering, acid uric lowering, glucose lowering, beta blockers or any drug that under the investigator's judged could influence the results.

  • Allergy/intolerance to any ingredient of the dietary supplements.
  • Chronic consumers of dietary NO-precursors dietary supplements (citrulline malate, arginine, nitrates).
  • Any non-controlled medical condition which could influence results or could be worsened by the participation in the study.
  • Are deemed unsuitable by the investigator for any other reason, that prevent data collection.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Experimental: L-Citrulline
5 g of L-citruline + 5 g of additives. The dose to be administered is that recommended on the labeling and nutritional information of the product, which has been produced under GMP procedures and approved by the EFSA (Lifepro®).
5 g of L-citruline + 5 g of additives
Experimental: Experimental: Citrulline-malate
8g of citrulline-malate + 2 g of additives. The dose to be administered is that recommended on the labeling and nutritional information of the products which has been produced under GMP procedures and approved by the EFSA (Lifepro®).
8g of citrulline-malate + 2 g of additives
Placebo Comparator: Placebo
10g of maltodextrin plus additives (Lifepro®).
10g of maltodextrine

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Maximal endurance strength
Time Frame: 1 hour
Maximal endurance strength of lower- and upper-body (squat and bench press exercises)
1 hour

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Maximal dynamic strength
Time Frame: 1 hour
Maximal dynamic strength of lower- and upper-body (squat and bench press exercises)
1 hour

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 15, 2022

Primary Completion (Actual)

June 30, 2022

Study Completion (Actual)

June 30, 2022

Study Registration Dates

First Submitted

December 21, 2021

First Submitted That Met QC Criteria

December 21, 2021

First Posted (Actual)

January 11, 2022

Study Record Updates

Last Update Posted (Actual)

November 4, 2022

Last Update Submitted That Met QC Criteria

November 3, 2022

Last Verified

November 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • Malate or Not Project

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Neuromuscular Performance

Clinical Trials on L-citrulline

3
Subscribe